Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prueba de combinación de erdafitinib y enfortumab vedotin en cáncer de vejiga metastásico después del tratamiento con quimioterapia e inmunoterapia

19 de septiembre de 2026 actualizado por: National Cancer Institute (NCI)

Ensayo de fase Ib de erdafitinib combinado con enfortumab vedotina después de inhibidores de platino y PD1/L1 para carcinoma urotelial metastásico con alteraciones genéticas FGFR2/3

This phase Ib trial evaluates the best dose, potential benefits, and/or side effects of erdafitinib in combination with enfortumab vedotin in treating patients with bladder cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and possesses genetic alterations in FGFR2/3 genes. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of cancer cells. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Giving erdafitinib in combination with enfortumab vedotin may shrink or stabilize metastatic bladder cancer with alterations in FGFR 2/3 genes.

Descripción general del estudio

Descripción detallada

PRIMARY OBJECTIVES:

I. To determine the feasibility and safety of erdafitinib when combined with enfortumab vedotin (EV) for patients with metastatic urothelial carcinoma (mUC) harboring FGFR2/3 activating genomic alterations who are progressing following platinum-based chemotherapy and PD1/L1 inhibitors.

II. To determine the maximally tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of EV when combined with erdafitinib.

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. II. To observe and record overall response rate (ORR). III. To observe and record duration of response (DOR). IV. To observe and record progression-free survival (PFS). V. To observe and record overall survival (OS).

EXPLORATORY OBJECTIVES:

I. Assess association of tumor PD-L1, nectin-4 protein, FGFR3, cell lineage markers and progression markers expression with response.

II. Use commercial tissue/plasma next generation sequencing (NGS) assay to confirm FGFR status as well as to describe the genomic landscape of metastatic UC.

III. Use commercial liquid NGS assay to assess genomic changes by circulating tumor (ct)-deoxyribonucleic acid (DNA) assessment to study mechanisms of resistance with treatment.

IV. Assess pharmacokinetic (PK) of monomethyl auristatin E (MMAE) and erdafitinib.

OUTLINE: This is a dose-escalation study of enfortumab vedotin in combination with fixed dose erdafitinib followed by a dose-expansion study of the drug combination.

Patients receive erdafitinib orally (PO) once daily (QD) on days 1-28 of each cycle and enfortumab vedotin intravenously (IV) over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and blood sample collection throughout the trial and may undergo echocardiography or multigated acquisition (MUGA) scan during screening and bone scan throughout the study.

After completion of study treatment, patients are followed up every 3 months for up to 2 years.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

24

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ontario
      • Toronto, Ontario, Canadá, M5G 2M9
        • University Health Network-Princess Margaret Hospital
    • California
      • Los Angeles, California, Estados Unidos, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Estados Unidos, 90033
        • Los Angeles General Medical Center
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • UCHealth University of Colorado Hospital
    • Florida
      • Tampa, Florida, Estados Unidos, 33612
        • Moffitt Cancer Center
    • New York
      • New York, New York, Estados Unidos, 10065
        • NYP/Weill Cornell Medical Center
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Ohio State University Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Hillman Cancer Center
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients must have histologically or cytologically documented locally advanced (T4b, any N; or any T, N 2-3) or metastatic (M1, Stage IV; or metastatic recurrence after locoregional treatment) urothelial carcinoma (including renal pelvis, ureters, urinary bladder, urethra). Patients with mixed histologies are required to have a dominant transitional cell pattern

  • Patients who had disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine and cisplatin [GC], methotrexate, vinblastine, doxorubicin and cisplatin [MVAC], carboplatin and gemcitabine [Carbo-Gem]) and an immune checkpoint inhibitor (PD-1/ PD-L1 inhibitor including but not limited to: atezolizumab, pembrolizumab, durvalumab, avelumab, and nivolumab)

    • Received a first-line platinum-containing regimen in the metastatic setting or for inoperable locally advanced disease
    • Or received neo/adjuvant platinum-containing therapy for localized muscle-invasive UC, with recurrence/progression =< 12 months following completion of therapy
    • Patients who received immune checkpoint inhibitor therapy in the neoadjuvant/adjuvant setting and had recurrent or progressive disease either during therapy or within 12 months of therapy completion are eligible. This criterion does not apply if the checkpoint inhibitor is contraindicated
  • Patients with metastatic urothelial carcinoma who are cisplatin-ineligible and progressed on upfront immune checkpoint inhibitor; or ineligible/refused immune checkpoint inhibitor therapy will be eligible for this trial

  • Patient who received prior antibody drug conjugate such as sacituzumab govitecan are allowed

  • Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Previously irradiated lesions cannot be counted as target lesions unless there has been demonstrated progression in the lesion since radiotherapy and no other lesions are available for selection as target lesions

  • Patients must have FGFR2/3 activating alterations identified by tumor tissue or plasma ctDNA profiling using a Clinical Laboratory Improvement Act (CLIA) certified College of American Pathologists (CAP) accredited platform

  • Age >= 18 years, for ability to comply with protocol

    • Because no dosing or adverse event data are currently available on the use of erdafitinib in combination with enfortumab vedotin in patients < 18 years of age, children are excluded from this study
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,500/mcL (within 14 days prior to beginning trial treatment)

  • Platelets >= 100,000/mcL (within 14 days prior to beginning trial treatment)

  • Hemoglobin >= 9 g/dL (within 14 days prior to beginning trial treatment)

  • Measured or calculated creatine clearance (CrCl) >= 30 ml/min (glomerular filtration rate [GFR] can also be used in place of creatinine CrCl) (within 14 days prior to beginning trial treatment)

  • Total bilirubin =< 1.5 x ULN (institutional upper limit of normal) OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 x ULN (within 14 days prior to beginning trial treatment)

  • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULN (=< 5 x ULN for subjects with liver metastasis) (within 14 days prior to beginning trial treatment)

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression (CNS metastases have been clinically stable for at least 4 weeks prior to screening and baseline scans show no evidence of new or enlarged metastasis)

  • Patients with a history of prostate cancer (T2NXMX or lower with Gleason score =< 7) treated with definitive intent (surgically or with radiation therapy) at least 1 year prior to study entry are eligible, provided that the subject is considered prostate cancer-free and the following criteria are met:

    • Patients who have undergone radical prostatectomy must have undetectable prostate specific antigen (PSA) for > 1 year and at screening
    • Patients who have had radiation must have a PSA doubling time > 1 year (based on at least 3 values determined >1 month apart) and a total PSA value that does not meet Phoenix criteria for biochemical recurrence (i.e., < 2.0 ng/mL above nadir)
    • Patients with untreated low-risk prostate cancer (Gleason score =< 6) on active surveillance with PSA doubling time >1 year (based on at least 3 values determined > 1 month apart) are also eligible
  • Patients who have undergone an ophthalmologic examination and have no active eye disease which would be likely to increase the risk of eye toxicity

  • The effects of erdafitinib and enfortumab vedotin on the developing human fetus are unknown. For this reason and because FGFR inhibitors and humanized antibody-drug conjugate (ADC) agents are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 3 months after completion of erdafitinib and enfortumab vedotin administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 5 months after completion of erdafitinib and enfortumab vedotin administration

  • Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy, targeted therapies, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (including ongoing sensory or motor neuropathy of grade 2 or higher) (i.e., have residual toxicities > grade 1 or returned to baseline) with the exception of alopecia. Subjects with =< grade 2 immunotherapy- related hypothyroidism or panhypopituitarism may be enrolled when well-maintained/controlled on a stable dose of hormone replacement therapy (if indicated). Subjects with ongoing >= grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy related colitis, uveitis, myocarditis, or pneumonitis or subjects with other immunotherapy related adverse events (AEs) requiring high doses of steroids (> 20 mg/day of prednisone or equivalent) are excluded

  • Patients who have previously received enfortumab vedotin or other MMAE-based ADCs

  • Patients who have had prior treatment with an FGFR inhibitor

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to erdafitinib and enfortumab vedotin

  • Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product

  • Patients with a history of any corneal or retinal abnormality likely to increase the risk of eye toxicity

  • Patients with uncontrolled intercurrent illness and currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of starting treatment. Routine antimicrobial prophylaxis is permitted

  • Patients with psychiatric illness/social situations that would limit compliance with study requirements

  • Subjects who have received radiotherapy within 2 weeks prior to start of treatment. Subject must have recovered adequately from the toxicity from the intervention prior to starting study treatment

  • Patients with uncontrolled diabetes. Uncontrolled diabetes is defined as hemoglobin A1c (HbA1c) >= 8% or HbA1c 7% to < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained

  • Subjects who have received major surgery within 4 weeks prior to start of treatment. Subject must have recovered adequately from complications from the intervention prior to starting study treatment

  • Subjects who have received a prior allogeneic stem cell or solid organ transplant

  • Has persistent phosphate level > ULN during screening (within 14 days of treatment and prior to cycle 1 day 1) and despite medical management

  • Has a history of or current uncontrolled cardiovascular disease including:

    • Unstable angina, myocardial infarction, or known congestive heart failure class II-IV within the preceding 12 months; cerebrovascular accident or transient ischemic attack within the preceding 3 months
    • Any of the following: sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, cardiac arrest, Mobitz II second degree heart block or third degree heart block; known presence of dilated, hypertrophic, or restrictive cardiomyopathy
    • Corrected QT interval (QTc) prolongation as confirmed by triplicate assessment at screening (Fridericia;QTc > 480 milliseconds)
  • Subjects with a history of another invasive malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with nonmelanoma skin cancer or carcinoma in situ of any type (if complete resection was performed) are allowed

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Treatment (erdafitinib, enfortumab vedotin)

Patients receive erdafitinib PO QD on days 1-28 of each cycle and enfortumab vedotin IV over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and blood sample collection throughout the trial and may undergo echocardiography or MUGA scan during screening and bone scan throughout the study.

Undergo blood sample collection

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

Undergo CT

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Undergo MUGA scan

Otros nombres:
  • Exploración de la piscina de sangre
  • Angiografía con radionúclidos de equilibrio
  • Imagen de piscina de sangre cerrada
  • MUGA
  • Ventriculografía con radionúclidos
  • RNVG
  • Escaneo SIMA
  • Escaneo de adquisición sincronizado de múltiples puertas
  • Escaneo MUGA
  • Escaneo de adquisición de puertas múltiples
  • Exploración de ventriculograma con radionúclidos
  • Escaneo de grupo de corazón cerrado
  • Escaneo RNV

Given PO

Otros nombres:
  • Balversa
  • JNJ-42756493
  • JNJ 42756493
  • JNJ42756493

Undergo bone scan

Otros nombres:
  • Gammagrafía ósea

Undergo echocardiography

Otros nombres:
  • Ecocardiografía
  • CE

Given IV

Otros nombres:
  • ASG-22CE
  • Padcev
  • AGS22ME
  • AGS-22M6E
  • Anti-Nectina 4 ADC ASG-22CE
  • Conjugado de fármaco-anticuerpo monoclonal anti-nectina-4 AGS-22M6E
  • Enfortumab Vedotin-ejfv
  • ASG 22CE
  • ASG22CE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidencia de eventos adversos
Periodo de tiempo: Hasta 2 años
Hasta 2 años
Dosis recomendada de fase II
Periodo de tiempo: Hasta 28 días
Hasta 28 días
Maximum tolerated dose of enfortumab vedotin
Periodo de tiempo: Up to 28 days

The highest dose of enfortumab vedotin in combination with fixed dose erdafitinib that does not cause unacceptable side effect.

Up to 28 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall response rate
Periodo de tiempo: Up to 2 years from study enrollment

Will be summarized using descriptive statistics including two-sided 95% confidence interval (CI) based on Clopper-Pearson method.

Up to 2 years from study enrollment
Duration of response
Periodo de tiempo: Time from complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years from study enrollment

Will be summarized using mean, standard deviation, median, and range.

Time from complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years from study enrollment
Progression free survival
Periodo de tiempo: Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years

Kaplan-Meier curve estimates of medians and their corresponding 95% CIs will be calculated.

Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years
Overall survival
Periodo de tiempo: Up to 2 years from study enrollment

Kaplan-Meier curve estimates of medians and their corresponding 95% CIs will be calculated.

Up to 2 years from study enrollment

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Expresión de PD-L1, Nectin-4, FGFR3/fosfo-FGFR3, linaje celular y marcadores de progresión
Periodo de tiempo: Hasta 2 años desde la inscripción en el estudio
Hasta 2 años desde la inscripción en el estudio
Tumor subtyping, tumor microenvironment, and mutations associated with treatment response
Periodo de tiempo: Up to 2 years from study enrollment

Will be evaluated based on pre-treatment sequencing data.

Up to 2 years from study enrollment
Mechanisms of resistance and response
Periodo de tiempo: Up to 2 years from study enrollment

Will be evaluated through peripheral blood circulating tumor deoxyribonucleic acid (DNA). Methods of analysis may include but not limited to, immunohistochemistry, next-generation sequencing of DNA and ribonucleic acid, and immunoassays.

Up to 2 years from study enrollment
Pharmacokinetics (PK)
Periodo de tiempo: Up to 2 years from study enrollment

PK analysis will be performed to explore the relationship between drug exposure, toxicity and response.

Up to 2 years from study enrollment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Rohit Jain, University Health Network Princess Margaret Cancer Center LAO

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de julio de 2022

Finalización primaria (Estimado)

1 de diciembre de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

14 de julio de 2021

Primero enviado que cumplió con los criterios de control de calidad

14 de julio de 2021

Publicado por primera vez (Actual)

15 de julio de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

19 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir